Clinical efficacy of botulinum toxin Type A combined with sodium hyaluronate solution facial microdrop injection to improve photoaging of facial skin

Clinical effect analysis of facial injection of botulinum toxin type A combined with sodium hyaluronate solution in anti-photoaging skin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400090466

Enrollment

Unknown

Registered

2024-09-30

Start date

2024-03-06

Completion date

Unknown

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

skin photoaging

Interventions

Monotherapy (sodium hyaluronate solution) :In the combination treatment group, only two drugs were used at the first injection (botulinum toxin type A 25u + sodium hyaluronate solution 5ml). Only 5ml

combination therapy (botulinum toxin type A + sodium hyaluronate solution):5ml sodium hyaluronate solution was injected in the second and third treatments in the single treatment group and the combine

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Beauty seekers who conform to Glogau skin photoaging classification and have the desire to improve facial rejuvenation can tolerate the corresponding treatment, and the treatment compliance is good. Before treatment, the skin elasticity, moisture content, elasticity, and luster were measured by a skin tester. It was confirmed that the skin had some photoaging problems, such as thickening of the stratum corneum, increased lipofercin, and decreased collagen, accompanied by neck relaxation, expression lines, crow's feet, bags under the eyes, and cheek displacement. Facial skin mild to moderate relaxation; Poor skin elasticity, overall thinning skin dark, etc.

Exclusion criteria

Exclusion criteria: Drug allergies or allergies used in this study; Being pregnant, breastfeeding or preparing for pregnancy; Blood system diseases; Combined with heart disease, diabetes and other basic diseases; Mental and cognitive dysfunction; Immune disease is present; Complicated with severe organ diseases; Combined with infectious disease or acute facial infection stage; Skin tumor; Unable to follow the doctor's advice on sunscreen, unwilling to actively cooperate with treatment; Scar constitution and so on.

Design outcomes

Primary

Measure	Time frame
CK five skin data (skin moisture content, transdermal water loss, elasticity, luster, pH);SOD and MDA levels in blood;2D Photography and Skin Condition Analysis (VISIA);	—

Secondary

Measure	Time frame
Clinical effect;GAIS score;Subject satisfaction;	—

Countries

China

Contacts

Public ContactPeisheng Jin

Affiliated Hospital of Xuzhou Medical University

jinps2006@163.com+86 138 5200 9951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026